Literature DB >> 19672209

Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma.

Thilo Welsch1, Shereen Keleg, Frank Bergmann, Sonja Bauer, Ulf Hinz, Jan Schmidt.   

Abstract

OBJECTIVES: Actinin-4 is an actin-bundling protein that probably has a tumor-promoting potential in several solid tumors. The present study analyzed the expression of actinin-4 in the pancreas, in localized and metastasized pancreatic ductal adenocarcinoma (PDAC), and the correlation with clinical outcome.
METHODS: Pancreatic ductal adenocarcinoma tissue from 38 patients, 15 lymph node and 10 liver metastases, normal pancreas, and 4 PDAC cell lines, were examined by immunohistochemistry, and actinin-4 expression was quantified by immunofluorescence analysis.
RESULTS: In the normal pancreas, actinin-4 was most prominently expressed in ductal cells. In PDAC, tumor cells exhibited strong but differential cytoplasmic immunoreactivity for actinin-4. A multivariate analysis revealed actinin-4 immunoreactivity, advanced age, and undifferentiated grade as significant prognostic factors associated with worse survival after PDAC resection. Cells metastasized to lymph nodes or to the liver exhibited no significant increase of actinin-4 compared with the primary tumors. A nuclear staining was observed neither in any of the PDAC samples nor in the 4 cell lines. In PDAC cells, actinin-4 localized to dynamic actin structures and to invadopodia.
CONCLUSIONS: Actinin-4 expression levels significantly correlate with worse survival after PDAC resection. Although actinin-4 has been reported to promote lymph node metastases, there was no enhanced expression in PDAC metastases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19672209     DOI: 10.1097/MPA.0b013e3181b28d6f

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  19 in total

1.  Proteomic analysis of differentially expressed proteins between stenotic and normal colon segment tissues derived from patients with Hirschsprung's disease.

Authors:  Hong Gao; Xiaojing He; Mei Wu; Zhibo Zhang; Dajia Wang; Liangying Lv; Zhenwei Su; Ying Huang
Journal:  Protein J       Date:  2011-02       Impact factor: 2.371

Review 2.  The fifth sense: Mechanosensory regulation of alpha-actinin-4 and its relevance for cancer metastasis.

Authors:  Dustin G Thomas; Douglas N Robinson
Journal:  Semin Cell Dev Biol       Date:  2017-06-01       Impact factor: 7.727

Review 3.  Force-dependent breaching of the basement membrane.

Authors:  Tammy T Chang; Dhruv Thakar; Valerie M Weaver
Journal:  Matrix Biol       Date:  2016-12-23       Impact factor: 11.583

Review 4.  Alpha-actinin 4 and tumorigenesis of breast cancer.

Authors:  Kuo-Sheng Hsu; Hung-Ying Kao
Journal:  Vitam Horm       Date:  2013       Impact factor: 3.421

5.  α-Actinin-4 enhances colorectal cancer cell invasion by suppressing focal adhesion maturation.

Authors:  Miki Fukumoto; Shusaku Kurisu; Tesshi Yamada; Tadaomi Takenawa
Journal:  PLoS One       Date:  2015-04-10       Impact factor: 3.240

6.  The actinin family of actin cross-linking proteins - a genetic perspective.

Authors:  Anita C H Murphy; Paul W Young
Journal:  Cell Biosci       Date:  2015-08-25       Impact factor: 7.133

7.  Calcium affinity of human α-actinin 1.

Authors:  Lars Backman
Journal:  PeerJ       Date:  2015-05-07       Impact factor: 2.984

Review 8.  The mechanobiome: a goldmine for cancer therapeutics.

Authors:  Eleana Parajón; Alexandra Surcel; Douglas N Robinson
Journal:  Am J Physiol Cell Physiol       Date:  2020-11-11       Impact factor: 4.249

9.  The biological role of actinin-4 (ACTN4) in malignant phenotypes of cancer.

Authors:  Kazufumi Honda
Journal:  Cell Biosci       Date:  2015-08-18       Impact factor: 7.133

Review 10.  The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.

Authors:  Daniel Ansari; Linus Aronsson; Agata Sasor; Charlotte Welinder; Melinda Rezeli; György Marko-Varga; Roland Andersson
Journal:  J Transl Med       Date:  2014-04-05       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.